Floatz logo

Palbociclib

Adult Solid Tumor

Abramson Cancer Center at Penn MedicineSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Adult Solid Tumor cohort.

Asset / SponsorPhaseRating
Pembrolizumab
CatalYm GmbH
Phase 2BB
Docetaxel
CatalYm GmbH
Phase 3B
Nivolumab
CatalYm GmbH
Phase 2B
Crofelemer
Napo Pharmaceuticals, Inc.
Phase 3B
Tazemetostat
Institut Bergonié
Phase 2B

View all 31 →

Same molecule, other indications

Palbociclib is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →